Skip to main content

Site notifications

SKYTROFA Specialised Therapeutics Pharma Pty Ltd

Product name
SKYTROFA
Accepted date
May-2024
Active ingredients
lonapegsomatropin
Proposed indication
Growth failure in children and adolescents due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]).
Application type
A (new medicine)
Publication date
May-2024

Help us improve the Therapeutic Goods Administration site